Table S1: Physical data of Substituted-1H-Pyrido[2,1-b] Quinazoline derivatives

S.No	Compounds	R_1	R_2	%Yield [a]	%Yield [b]
1	**4a**	H	C_6H_5	50	72
2	**4b**	H	4-ClC_6H_4	62	74
3	**4c**	H	4-$NO_2C_6H_4$	68	76
4	**4d**	H	4-$OCH_3C_6H_4$	68	82
5	**4e**	H	4-$CH_3C_6H_4$	65	72
6	**4f**	4-Cl	4-ClC_6H_4	69	77
7	**4g**	4-Cl	4-FC_6H_4	68	74
8	**4h**	H	3,4,5-$OCH_3C_6H_4$	69	79
9	**4i**	H	1-Benzyl-1H-Indole-3-Carbaldehyde	67	75
10	**4j**	H	Indole-3-Carbaldehyde	68	77

Table S2: Docking interactions of 4q, 4r and erlotinib with EGFR kinase

			Interactions (Distance)			
S.NO	**Compound**	**Dock Score**	**H-Bond**	**pi-H**	**Hydrophobic**	**Energy (kcal/mol)**
1	**4q**	-6.34		Val702	Phe 699, Leu 694, Met 742 and Leu 764	-17.47
2	**4r**	-5.96		Val702, Lys 721	Phe 699, Leu 694, Met 742 and Leu 764	-16.57
	erlotinib	-7.29	Met769		Phe699, Leu694, Met742, Val702, Leu768	-22.34